Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; A preliminary clinical study

Duman B. B. , Kara B., KARA İ. O. , Demiryurek H., Aksungur E.

JOURNAL OF BUON, cilt.16, sa.4, ss.759-764, 2011 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 16 Konu: 4
  • Basım Tarihi: 2011
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayıları: ss.759-764


Purpose: Sorafenib has been found to have significant clinical activity against hepatocellular carcinoma (HCC). Hand-foot skin syndrome (HFS) has been described with the usage of sorafenib. It is a dose-limiting toxicity and may lead to compromised efficacy because of dose reduction.